Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Posts Earnings Results, Misses Expectations By $0.74 EPS

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) announced its quarterly earnings results on Thursday. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.74), Yahoo Finance reports. Calliditas Therapeutics AB (publ) had a negative net margin of 40.19% and a negative return on equity of 133.08%. The company had revenue of $28.43 million during the quarter, compared to analyst estimates of $35.78 million.

Calliditas Therapeutics AB (publ) Price Performance

Shares of Calliditas Therapeutics AB (publ) stock traded down $0.33 during trading on Friday, hitting $22.42. 13,209 shares of the company’s stock traded hands, compared to its average volume of 3,506. The company has a debt-to-equity ratio of 2.89, a current ratio of 3.13 and a quick ratio of 3.08. The firm’s fifty day moving average price is $20.60 and its 200 day moving average price is $21.15. Calliditas Therapeutics AB has a twelve month low of $15.25 and a twelve month high of $29.30. The company has a market cap of $667.89 million, a PE ratio of -13.67 and a beta of 1.50.

Analyst Ratings Changes

Separately, HC Wainwright dropped their price target on shares of Calliditas Therapeutics AB (publ) from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Friday.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.